Leona Markson
About Leona Markson
Leona Markson serves as the HEOR Global Lead for Arikayce at Insmed Incorporated, where she emphasizes cross-functional collaboration and contributes to global strategic initiatives. With a distinguished academic background and extensive experience in healthcare policy and research, she has held leadership roles at various prominent organizations, including Pfizer and Merck.
Current Role at Insmed
Leona Markson serves as the HEOR Global Lead for Arikayce at Insmed Incorporated. In this role, she has been involved in leading the Medical Affairs sub-team of the Global Asset Team since 2023. Her responsibilities include emphasizing cross-functional collaboration and contributing to global strategic initiatives related to the company's products.
Education and Expertise
Leona Markson holds a Bachelor of Science degree with distinction from Penn State University. She furthered her education at the Johns Hopkins Bloomberg School of Public Health, where she studied for a Doctor of Science (ScD) and achieved a Master of Health Science (MHS). Her educational background supports her expertise in health economics and outcomes research.
Professional Background
Leona Markson has a diverse professional background in healthcare and research. She worked at Jefferson Medical College as a Research Associate Professor of Medicine and Associate Director of Clinical Outcomes Research from 1988 to 1995. She also held positions at Pfizer as Senior Director of Health Economics & Outcomes Research from 2019 to 2023 and at Merck as Executive Director from 1995 to 2018.
Contributions to Healthcare Policy
Leona Markson actively contributes to policy discussions focused on quality and accountability in healthcare. She has held Board of Director and Scientific Advisory positions aimed at advancing medical care and expanding the use of real-world evidence in healthcare decision-making.
Leadership in Health Economics and Outcomes Research
During her tenure at Pfizer, Leona Markson co-chaired the Integrated Evidence Team, where she focused on strategic leadership in health economics and outcomes research. Her leadership roles have emphasized the importance of value evidence in the healthcare sector.